Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026

Eton Pharmaceuticals, Inc.

Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.
Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.
Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.
Gruber to provide transition support via six-month consulting agreement.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Gruber

Chief Financial Officer

Eton Pharmaceuticals, Inc.

Effective: 2026-06-01
Successor: Judith Matthews
Filed: Apr 16, 2026 23:59 UTC

Mr. Gruber will remain in his role with the Company through May 31, 2026 and will subsequently enter into a six-month consulting agreement with the Company.

Appointed

Judith Matthews

Chief Financial Officer

Eton Pharmaceuticals, Inc.

Effective: 2026-06-01
Filed: Apr 16, 2026 23:59 UTC

Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.

Source: SEC EDGAR

accession 0001437749-26-012488

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.